Clinical ergotism induced by ritonavir

Area of Science:

• Pharmacology
• Drug Metabolism
• HIV/AIDS Therapeutics

Background:

• Ritonavir is a protease inhibitor used in HIV therapy.
• Cytochrome P450 enzymes are crucial for drug metabolism.
• Drug interactions are a significant concern in managing HIV patients.

Observation:

• An HIV-positive individual developed severe ergotism.
• Symptoms appeared on the 13th day of ritonavir therapy.
• The patient self-administered low doses of ergotamine.

Findings:

• Ritonavir strongly inhibits cytochrome P450.
• This inhibition altered the metabolism of ergotamine.
• A severe drug interaction occurred between ritonavir and ergotamine.

Implications:

• Healthcare providers must consider potential drug interactions with ritonavir.
• Patient education on medication use, including over-the-counter drugs, is vital.
• Careful prescribing of antiretroviral therapy is necessary to prevent adverse events.